AU2012225766B9 - Peptide linkers for polypeptide compositions and methods for using same - Google Patents

Peptide linkers for polypeptide compositions and methods for using same Download PDF

Info

Publication number
AU2012225766B9
AU2012225766B9 AU2012225766A AU2012225766A AU2012225766B9 AU 2012225766 B9 AU2012225766 B9 AU 2012225766B9 AU 2012225766 A AU2012225766 A AU 2012225766A AU 2012225766 A AU2012225766 A AU 2012225766A AU 2012225766 B9 AU2012225766 B9 AU 2012225766B9
Authority
AU
Australia
Prior art keywords
peptide
amino acid
seq
acid sequence
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012225766A
Other languages
English (en)
Other versions
AU2012225766A1 (en
AU2012225766B2 (en
Inventor
Michael Concino
Paolo Martini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Human Genetics Therapies Inc
Original Assignee
Shire Human Genetics Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/041928 external-priority patent/WO2011163652A2/en
Application filed by Shire Human Genetics Therapies Inc filed Critical Shire Human Genetics Therapies Inc
Publication of AU2012225766A1 publication Critical patent/AU2012225766A1/en
Priority to AU2017204405A priority Critical patent/AU2017204405B2/en
Publication of AU2012225766B2 publication Critical patent/AU2012225766B2/en
Application granted granted Critical
Publication of AU2012225766B9 publication Critical patent/AU2012225766B9/en
Priority to AU2019202865A priority patent/AU2019202865B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2012225766A 2011-03-04 2012-03-02 Peptide linkers for polypeptide compositions and methods for using same Active AU2012225766B9 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2017204405A AU2017204405B2 (en) 2011-03-04 2017-06-28 Peptide linkers for polypeptide compositions and methods for using same
AU2019202865A AU2019202865B2 (en) 2011-03-04 2019-04-24 Peptide linkers for polypeptide compositions and methods for using same

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161449225P 2011-03-04 2011-03-04
US61/449,225 2011-03-04
US13/168,969 2011-06-25
PCT/US2011/041928 WO2011163652A2 (en) 2010-06-25 2011-06-25 Treatment of sanfilippo syndrome type b
AUPCT/US2011/041928 2011-06-25
US13/168,969 US20110318327A1 (en) 2010-06-25 2011-06-25 Treatment of sanfilippo syndrome type b
PCT/US2012/027561 WO2012122042A2 (en) 2011-03-04 2012-03-02 Peptide linkers for polypeptide compositions and methods for using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017204405A Division AU2017204405B2 (en) 2011-03-04 2017-06-28 Peptide linkers for polypeptide compositions and methods for using same

Publications (3)

Publication Number Publication Date
AU2012225766A1 AU2012225766A1 (en) 2013-09-19
AU2012225766B2 AU2012225766B2 (en) 2017-07-13
AU2012225766B9 true AU2012225766B9 (en) 2017-08-31

Family

ID=49165891

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2012225766A Active AU2012225766B9 (en) 2011-03-04 2012-03-02 Peptide linkers for polypeptide compositions and methods for using same
AU2017204405A Active AU2017204405B2 (en) 2011-03-04 2017-06-28 Peptide linkers for polypeptide compositions and methods for using same
AU2019202865A Expired - Fee Related AU2019202865B2 (en) 2011-03-04 2019-04-24 Peptide linkers for polypeptide compositions and methods for using same

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2017204405A Active AU2017204405B2 (en) 2011-03-04 2017-06-28 Peptide linkers for polypeptide compositions and methods for using same
AU2019202865A Expired - Fee Related AU2019202865B2 (en) 2011-03-04 2019-04-24 Peptide linkers for polypeptide compositions and methods for using same

Country Status (7)

Country Link
EP (1) EP2680879B1 (enExample)
JP (3) JP6175372B2 (enExample)
CN (2) CN106279433A (enExample)
AU (3) AU2012225766B9 (enExample)
BR (1) BR112013022557A2 (enExample)
CA (2) CA3080181A1 (enExample)
WO (1) WO2012122042A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
ES2679374T3 (es) 2012-11-27 2018-08-24 Biomarin Pharmaceutical Inc. Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas
WO2016025523A1 (en) 2014-08-11 2016-02-18 Shire Human Genetic Therapies, Inc. Lysosomal targeting and uses thereof
MA41022A (fr) 2014-11-24 2017-10-03 Shire Human Genetic Therapies Ciblage lysosomial et utilisations correspondantes
WO2020236755A2 (en) * 2019-05-17 2020-11-26 Ionis Pharmaceuticals, Inc. Angiotensin ii type 1 receptor targeted oligonucleotides and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005824A2 (en) * 1999-07-15 2001-01-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic peptides immunoreactive with hepatitis a virus antibodies
JP2005170810A (ja) * 2003-12-09 2005-06-30 Sanyo Chem Ind Ltd 細胞接着性ポリペプチド
US20060099218A1 (en) * 2002-10-01 2006-05-11 Dnavec Research Method of strengthening foreign epitope presentation by mhc class i by inhibiting tap activity
WO2006129085A2 (en) * 2005-06-01 2006-12-07 Medigene Limited High affinity melan-a t cell receptors
US20080039341A1 (en) * 2005-09-27 2008-02-14 Volker Schellenberger Unstructured recombinant polymers and uses thereof
WO2010080424A1 (en) * 2008-12-18 2010-07-15 E. I. Du Pont De Nemours And Company Peptide linkers for effective multivalent peptide binding
WO2011163652A2 (en) * 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Treatment of sanfilippo syndrome type b

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996037621A2 (en) * 1995-05-23 1996-11-28 Morphosys Gesellschaft Für Proteinoptimierung Mbh Multimeric proteins
US20040181830A1 (en) * 2001-05-07 2004-09-16 Kovalic David K. Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
CN101287748B (zh) * 2005-04-20 2013-03-27 百疗医株式会社 一种融合蛋白的组成及其分离方法
GB0524987D0 (en) * 2005-12-08 2006-01-18 Ge Healthcare Ltd Novel imaging agents for fibrosis
GB0611463D0 (en) * 2006-06-09 2006-07-19 Novartis Ag Organic compounds
EP2190861A4 (en) * 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
EP2223934B1 (en) * 2007-11-14 2012-10-03 Institute Of Microbiology, Chinese Academy Of Sciences Polypeptides for inhibiting influenza virus infection
CN101186637B (zh) * 2007-11-14 2011-09-14 中国科学院微生物研究所 抑制流感病毒感染的方法及其药物
WO2009137721A2 (en) * 2008-05-07 2009-11-12 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
TWI496582B (zh) * 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
CN102365295A (zh) * 2009-01-30 2012-02-29 阿德利夫股份有限公司 构象动力肽

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005824A2 (en) * 1999-07-15 2001-01-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic peptides immunoreactive with hepatitis a virus antibodies
US20060099218A1 (en) * 2002-10-01 2006-05-11 Dnavec Research Method of strengthening foreign epitope presentation by mhc class i by inhibiting tap activity
JP2005170810A (ja) * 2003-12-09 2005-06-30 Sanyo Chem Ind Ltd 細胞接着性ポリペプチド
WO2006129085A2 (en) * 2005-06-01 2006-12-07 Medigene Limited High affinity melan-a t cell receptors
US20080039341A1 (en) * 2005-09-27 2008-02-14 Volker Schellenberger Unstructured recombinant polymers and uses thereof
WO2010080424A1 (en) * 2008-12-18 2010-07-15 E. I. Du Pont De Nemours And Company Peptide linkers for effective multivalent peptide binding
WO2011163652A2 (en) * 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Treatment of sanfilippo syndrome type b

Also Published As

Publication number Publication date
EP2680879B1 (en) 2021-01-06
WO2012122042A2 (en) 2012-09-13
JP6175372B2 (ja) 2017-08-02
CA3080181A1 (en) 2012-09-13
WO2012122042A3 (en) 2014-03-13
AU2019202865B2 (en) 2021-04-01
BR112013022557A2 (pt) 2017-08-01
CA2828966C (en) 2020-07-14
AU2019202865A1 (en) 2019-05-16
EP2680879A4 (en) 2015-09-02
AU2017204405B2 (en) 2019-05-09
CA2828966A1 (en) 2012-09-13
AU2017204405A1 (en) 2017-07-20
CN103764162B (zh) 2017-03-08
EP2680879A2 (en) 2014-01-08
AU2012225766A1 (en) 2013-09-19
CN103764162A (zh) 2014-04-30
AU2012225766B2 (en) 2017-07-13
JP2014515595A (ja) 2014-07-03
CN106279433A (zh) 2017-01-04
JP6594833B2 (ja) 2019-10-23
JP2016187358A (ja) 2016-11-04
JP2019150065A (ja) 2019-09-12

Similar Documents

Publication Publication Date Title
US9932568B2 (en) Peptide linkers for polypeptide compositions and methods for using same
AU2019202865B2 (en) Peptide linkers for polypeptide compositions and methods for using same
EP1981546B1 (en) Enzyme replacement therapy for treating lysosomal storage diseases
EP3272773B1 (en) Lyosomal targeting peptides and uses thereof
EP3115372B1 (en) Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
WO2015009052A1 (ko) 하이브리드 면역글로불린 fc와 효소의 융합단백질
HK1193352A (en) Peptide linkers for polypeptide compositions and methods for using same
HK1193352B (en) Peptide linkers for polypeptide compositions and methods for using same
HK1250042B (en) Lysosomal targeting peptides and uses thereof
HK1232896B (en) Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
HK1232896A1 (en) Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
HK1216026B (en) Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)